C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Patents for C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
12/2001
12/06/2001	WO2001019800A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto
12/06/2001	WO2001017999A3 Amino-triazolopyridine derivatives
12/06/2001	WO2001010847A8 Novel integrin receptor antagonists
12/06/2001	US20010049441 An azaindole derivative useful for antagonizing 5-HT6 receptor
12/06/2001	US20010049379 Nitric oxide synthase inhibitors; treatment and prevention of central nervous system and other disorders.
12/06/2001	US20010049371 Reducing levels of tumor necrosis factor alpha; inhibition of undesireable levels of matrix metalloproteinases
12/06/2001	CA2410597A1 Melanocortin receptor agonists
12/06/2001	CA2409617A1 2,7-naphthyridine derivatives
12/05/2001	EP1159964A2 Compositions and methods for stimulating gastrointestinal motility
12/05/2001	EP1159277A1 Crystal modification d of 8-cyano-1-cyclopropyl-7- (1s, 6s- 2,8- diazabicyclo- 4.3.0] nonan-8-yl) -6-fluoro -1,4-dihydro -4-oxo -3-quinoline carboxylic acid
12/05/2001	EP1158986A1 Protease inhibitors
12/05/2001	EP1158980A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
12/05/2001	EP0911327B1 Novel pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient
12/05/2001	EP0835244B1 Diheterocyclic acrylonitriles as smooth muscle cell proliferation inhibitors
12/05/2001	CN1325399A Pyrroloindoles, pyridoindoles and azepinoindoles as 5-HT2c agonists
12/05/2001	CN1325390A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
12/05/2001	CN1325306A Pharmaceutical moxifloxacin preparation
12/05/2001	CN1325267A Fused-benzene derivatives useful as herbicides
12/04/2001	US6326495 Heating a mixture of caprolactone and p-methoxybenzylamine; cyclization
12/04/2001	US6326494 1,7-Diaroxy- or 1,7-arylthio-substituted perylene-3,4,9,10-tetracarboxylic acids, their dianhydrides and diimides
12/04/2001	US6326388 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
12/04/2001	US6326380 Thrombin receptor antagonists
12/04/2001	US6326379 Fused pyridine inhibitors of cGMP phosphodiesterase
12/04/2001	US6326375 Containing an urea group
12/04/2001	CA2110260C Pyridonecarboxylic acid derivatives
11/2001
11/29/2001	WO2001090109A1 Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
11/29/2001	WO2001090101A1 Arylmethylamine derivatives for use as tryptase inhibitors
11/29/2001	WO2001089497A2 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
11/29/2001	WO2001089482A2 Method for preparing microparticles having a selected polymer molecular weight
11/29/2001	WO2001046150A3 Quinolone compounds for use in treating viral infections
11/29/2001	WO2001030780A3 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
11/29/2001	WO2000055159A3 Substituted aza-oxindole derivatives
11/29/2001	US20010047007 Tyrosine kinase inhibitors
11/29/2001	US20010047006 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
11/29/2001	US20010046989 Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
11/29/2001	US20010046983 Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
11/29/2001	US20010044974 Oxidation color dyes
11/29/2001	CA2409644A1 Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
11/28/2001	EP1158321A2 Dichroic light polarizers with non-periodic arrangement of different polarizing elements
11/28/2001	EP1158320A2 Dichroic light polarizers
11/28/2001	EP1157726A1 Reactive crystallization method to improve particle size
11/28/2001	EP1157704A1 Remedies or preventives for ischemic reflow failure
11/28/2001	EP1157025A1 Pyrazolopyridines
11/28/2001	EP1157024A1 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors
11/28/2001	EP1157021A1 Sulfamato hydroxamic acid metalloprotease inhibitor
11/28/2001	EP1156808A2 Enhancement of return to independent living status with a growth hormone secretagogue
11/28/2001	EP1156807A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
11/28/2001	EP0787726B1 Novel compound, process for producing the same, and antitumor agent
11/28/2001	EP0784054B1 1,2,3,4-tetrahydroquinoxalinedione derivatives and use as glutamate receptor antagonists
11/28/2001	EP0783503B1 2,7-substituted octahydro-1h-pyrido[ 1,2-a]pyrazine derivatives
11/28/2001	EP0695303B1 Pyridinium salts and their use for controlling helicobacter bacteria
11/28/2001	CN1324359A Tricyclic carboxamides
11/28/2001	CN1324358A Imidazo [4,5-C-] pyridine-4-one derivatives with factor XA inhibiting effect
11/28/2001	CN1323799A Biological medicine precursor [1,2-alpha] imidazopyridine halide and its prepn.
11/28/2001	CN1075499C Quninolone-acid naphthyridone carboxylic acid derivatives
11/28/2001	CN1075498C Charleston C-glucoside and its uses
11/27/2001	US6323230 Epicuaneous route in the case of dermatological illnesses like psoriasis, atopic dermatitis and other similar affections, or when administered by oral or rectal route in the case of diseases of the epithelia of the lower intestines
11/27/2001	US6323229 Compounds are useful psychotherapeutics and are potent agonists and/or antagonists of the serotonin 1a (5-ht 1a) and/or serotonin 1d (5-ht 1d) for treatment of hypertension, depression, generalized anxiety disorder
11/27/2001	US6323227 Prodrugs
11/27/2001	US6323217 Cardiovascular disorders
11/27/2001	US6323216 Selective antagonists of the 5-ht.sub.3 serotonin-like receptor and can therefore be used, as anti-emetics as well as in various pathological conditions of the central nervous system, and as antitussives.
11/27/2001	US6323213 Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
11/27/2001	US6323208 Compounds to treat neurodegenerative, psychotropic drug and alcohol induced central and induced central and peripheral nervous system disorders.
11/27/2001	US6323194 Muscarinic agonists and antagonists
11/27/2001	CA2214037C Method of making camptothecin and camptothecin analogs
11/26/2001	CA2349136A1 Reactive crystallization method to improve particle size
11/22/2001	WO2001087895A1 Synthetic process for the manufacture of an ecteinaschidin compound
11/22/2001	WO2001087894A1 Antitumoral analogs of et-743
11/22/2001	WO2001087887A2 Neuroprotective and anti-proliferative compounds
11/22/2001	WO2001087886A1 Crf receptor antagonists and methods relating thereto
11/22/2001	WO2001087885A1 Crf receptor antagonists
11/22/2001	WO2001087883A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
11/22/2001	WO2001087882A2 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
11/22/2001	WO2001087845A2 N-containing heterocyclic compounds and their use as 5-ht antagonists
11/22/2001	WO2001087844A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
11/22/2001	WO2001087838A1 Cyclohexane derivatives and their use as therapeutic agents
11/22/2001	WO2001087828A1 N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
11/22/2001	WO2001087308A1 Treatment of fibromyalgia and chronic fatigue syndrome
11/22/2001	WO2001087305A2 Method for treating functional dyspepsia using alosetron
11/22/2001	WO2001087235A2 Method for producing[18f]fluoride ion
11/22/2001	WO2001087038A2 β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE
11/22/2001	WO2001030781A3 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
11/22/2001	WO2001030752A3 Indole compounds for treating bacterial infections
11/22/2001	WO2001029050A3 Condensed pyrrole derivatives as neuraminidase inhibitors
11/22/2001	WO2001027116A3 Condensed dihydroquinolinone derivatives for inhibiting mrp1
11/22/2001	US20010044538 Mitogen-activated protein (MAP) kinase; treating inflammatory diseases; compounds such as 3-(4-fluorophenyl)-1-hydroxy-2-(pyridin-4-yl)-1H-pyrrolo(3,2-b)pyridine
11/22/2001	US20010044535 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
11/22/2001	US20010044451 Tyrosine kinase inhibitors
11/22/2001	US20010044443 Fungicidal active compound combinations
11/22/2001	US20010044439 Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists
11/22/2001	US20010044436 Bicyclic inhibitors of glycogen synthase kinase 3
11/22/2001	CA2408849A1 Cyclohexane derivatives and their use as therapeutic agents
11/22/2001	CA2404704A1 Treatment of fibromyalgia and chronic fatigue syndrome
11/21/2001	EP1156050A2 Substituted tricyclics useful in sPLA2 induced diseases
11/21/2001	EP1155018A1 Crystal modification c of 8-cyano-1-cyclopropyl-7- (1s, 6s-2,8- diazabicyclo - 4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic
11/21/2001	EP1155017A1 [1,8] naphthyridine derivatives having antiviral activity
11/21/2001	EP1155007A2 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
11/21/2001	EP1155001A1 Isoquinoline derivatives and isoquinoline combinatorial libraries
11/21/2001	EP1154997A1 Pharmaceutically active compounds and methods of use thereof
11/21/2001	EP1154774A1 Quinazoline derivatives as angiogenesis inhibitors

1 ... 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 ... 646